Roles of lncRNA-MALAT1 in the Progression and Prognosis of Gliomas

• Published in: Mini reviews in medicinal chemistry Vol. 24; no. 8; p. 786
• Main Authors: Ji, Yu-Long, Kang, Kai, Lv, Qiao-Li, Wang, Da-Peng
• Format: Journal Article
• Language: English
• Published: Netherlands 01.01.2024
• Subjects: Brain Neoplasms - drug therapy; Brain Neoplasms - genetics; Brain Neoplasms - metabolism; Brain Neoplasms - pathology; Disease Progression; Glioma - drug therapy; Glioma - genetics; Glioma - metabolism; Glioma - pathology; Humans; Prognosis; RNA, Long Noncoding - genetics; RNA, Long Noncoding - metabolism; glioma; biological process; long non-coding RNA; drug resistance; Gliomas; prognosis therapetic drug
• ISSN: 1875-5607
• DOI: 10.2174/0113895575253875230922055711

Long noncoding RNAs (lncRNAs) represent a large subgroup of RNA transcripts that lack the function of coding proteins and may be essential universal genes involved in carcinogenesis and metastasis. LncRNA metastasis-associated lung adenocarcinoma transcript 1 (lncRNAMALAT1) is overexpressed in various human tumors, including gliomas. However, the biological function and molecular mechanism of action of lncRNA-MALAT1 in gliomas have not yet been systematically elucidated. Accumulating evidence suggests that the abnormal expression of lncRNA-MALAT1 in gliomas is associated with various physical properties of the glioma, such as tumor growth, metastasis, apoptosis, drug resistance, and prognosis. Furthermore, lncRNAs, as tumor progression and prognostic markers in gliomas, may affect tumorigenesis, proliferation of glioma stem cells, and drug resistance. In this review, we summarize the knowledge on the biological functions and prognostic value of lncRNA-MALAT1 in gliomas. This mini-review aims to deepen the understanding of lncRNA-MALAT1 as a novel potential therapeutic target for the individualized precision treatment of gliomas.